Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions
- PMID: 19540167
- DOI: 10.1016/j.transci.2009.05.011
Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions
Abstract
CD34+ peripheral blood hematopoietic stem cells (HSC) are usually collected following mobilization therapy accomplished by using growth factors (GF) such as rHuG-CSF or rHuGM-CSF with or without chemotherapy. A target dose of yielded CD34+ is usually prescribed by the attending physician depending on different protocols, which may include single or double transplantation. HSC collection usually is performed when at least 20 CD34+ HSC/microL are detected by means of flow cytometry. A cumulative dose of at least 2 x 10(6)/Kg/bw CD34+ HSC has been considered as the threshold to allow a prompt and persistent hematopoietic recovery. Unfortunately, this goal is not achieved by the totality of patients undergoing mobilization regimen. In fact, 5-46% of patients who underwent mobilization therapy fail HSC collection due to very low peripheral blood HSC CD34+ count. Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization. We performed a retrospective analysis in 2177 patients from three large Italian academic institutions to assess the incidence of poor mobilizers within our patients' series. Therefore, a patient who fails a first mobilization (and when an HLA-compatible related on unrelated donor is not available) could undergo a second attempt either with different mobilization schedule or by using different GF, such as stem cell factor, growth hormone (GH), or more recently newly introduced drugs such as AMD3100, alone or in combination with rHuG- or -rHuGM-CSF. Thus, we investigated the fate of those who failed a first mobilization and subsequently underwent a second attempt or alternative therapeutic approaches.
Similar articles
-
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.Transfusion. 2007 Dec;47(12):2207-16. doi: 10.1111/j.1537-2995.2007.01448.x. Epub 2007 Aug 21. Transfusion. 2007. PMID: 17714420
-
Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404. doi: 10.1016/j.bbmt.2004.02.001. Biol Blood Marrow Transplant. 2004. PMID: 15148493 Clinical Trial.
-
Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen.Bone Marrow Transplant. 2005 Sep;36(5):389-96. doi: 10.1038/sj.bmt.1705069. Bone Marrow Transplant. 2005. PMID: 15980882 Clinical Trial.
-
Management strategies for poor peripheral blood stem cell mobilization.Transfus Apher Sci. 2008 Jun;38(3):229-36. doi: 10.1016/j.transci.2008.04.002. Epub 2008 May 15. Transfus Apher Sci. 2008. PMID: 18485822 Review.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
Cited by
-
Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients.Transfus Med Hemother. 2022 Sep 5;50(1):39-50. doi: 10.1159/000525565. eCollection 2023 Feb. Transfus Med Hemother. 2022. PMID: 36818774 Free PMC article.
-
Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients.Transfus Med Hemother. 2023 Jun 5;50(5):382-395. doi: 10.1159/000530056. eCollection 2023 Oct. Transfus Med Hemother. 2023. PMID: 37899996 Free PMC article.
-
Exercise as an Adjuvant Therapy for Hematopoietic Stem Cell Mobilization.Stem Cells Int. 2016;2016:7131359. doi: 10.1155/2016/7131359. Epub 2016 Mar 31. Stem Cells Int. 2016. PMID: 27123008 Free PMC article. Review.
-
Establishment of a humanized mouse model using steady-state peripheral blood-derived hematopoietic stem and progenitor cells facilitates screening of cancer-targeted T-cell repertoires.Cancer Innov. 2024 Apr 15;3(3):e118. doi: 10.1002/cai2.118. eCollection 2024 Jun. Cancer Innov. 2024. PMID: 38947755 Free PMC article.
-
Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model.BMB Rep. 2017 Aug;50(8):417-422. doi: 10.5483/bmbrep.2017.50.8.099. BMB Rep. 2017. PMID: 28712386 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials